Clinical trials: Liraglutide
Therapeutic Equivalency
A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects
The study was designed as a single-site, randomized, open-label, crossover under fasted conditions. A single oral dose of 0.6 mg Liraglutide injection and Victoza® was given to the 32 healthy Chinese adult male volunteers.Blood…
- Trial name
- NCT05225974
- Testing
- Liraglutide injection, Liraglutide injection(Victoza®)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Obese, Overweight
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect and safety of Liraglutide Injection on body weight loss compared with placebo in obese or overweight adult patients with comorbidity…
- Trial name
- NCT04605861
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Metabolic Syndrome
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume…
- Trial name
- ZQL008 (NCT04575844)
- Testing
- Liraglutide, Exercise training, Liraglutide + Exercise training
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Obesity
GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations
The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases.
- Trial name
- NCT02082496
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01507285
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT05794581
- Testing
- CT-868, Victoza
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
GLP-1；Metformin；Telomere-telomerase System；Par-4
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
- Trial name
- Par-4；GLP-1 (NCT02535299)
- Testing
- Liraglutide, Metformin
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Obesity
Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
Introduction: The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss…
- Trial name
- S-LITE (NCT04122716)
- Testing
- Liraglutide, Exercise
- Where
- Denmark
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with…
- Trial name
- NCT04903509
- Testing
- BI 1820237, Saxenda®, Paracetamol-ratiopharm®
- Where
- Germany
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.
- Trial name
- NCT01722266
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the…
- Trial name
- NCT03292185
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
This study aims to investigate the acute effects of Liraglutide, a GLP-1 receptor agonist established in the treatment of type 2 diabetes and obesity, on brain metabolism, brain network function, and executive functioning as well…
- Trial name
- GLPsy (NCT06818292)
- Testing
- Liraglutide
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Nils Opel
Obesity
To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity
The study is a single center, randomized, double blind, placebo controlled; parallel-group repeated measures design. Subjects will be randomly assigned to either Saxenda® or placebo group after baseline assessments.
- Trial name
- NCT03795701
- Testing
- Saxenda®
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers
This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of NNC 90-1170 (liraglutide) in healthy Japanese male subjects.
- Trial name
- NCT01620463
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S